---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-028200"
form_type: "8-K"
ticker: "CRDF"
cik: "0001213037"
company_name: "Cardiff Oncology, Inc."
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T08:08:47.928529+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cardiff Oncology Q3 cash burn $7.5M; Phase 1b/2 mCRC data show 35% ORR; ONSEMBLE trial on track for Q4 activation

## Summary
- Cash, equivalents, and investments $114M as of Sep 30, 2022; projected runway into 2025.
- Q3 2022 net cash used in operations $7.5M vs $5.5M in Q3 2021.
- Phase 1b/2 mCRC trial: ORR 35% (n=48), mPFS 9.3 months, mDoR 11.7 months.
- ONSEMBLE randomized Phase 2 trial in KRAS/NRAS-mutated mCRC activation expected Q4 2022.
- Bevacizumab-naïve subgroup ORR 69% and mPFS 13.5 months vs historical ~25% and 6.9 months.

## SEC filing metadata
- accession: 0001628280-22-028200
- form_type: 8-K
- ticker: CRDF
- cik: 0001213037
- company_name: Cardiff Oncology, Inc.
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1213037/000162828022028200/0001628280-22-028200-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1213037/000162828022028200/crdf-20221103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-028200
- JSON: https://secwatch.observer/filing/0001628280-22-028200.json
- Plain text: https://secwatch.observer/filing/0001628280-22-028200.txt

## Key facts
- Earnings Releases
  Cardiff Oncology, Inc. reported financial results for the third quarter ended September 30, 2022.
  - Period: the third quarter ended September 30, 2022
  - Result: reported results
  source text: On November 3, 2022, Cardiff Oncology, Inc. issued a press release announcing company highlights and financial results for the third quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1213037/000162828022028200/0001628280-22-028200-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.